Drug Profile
Fonadelpar - Senju Pharmaceutical
Alternative Names: SJP 0035Latest Information Update: 27 Jul 2022
Price :
$50
*
At a glance
- Originator Senju Pharmaceutical
- Class Acetic acids; Benzoxazoles; Eye disorder therapies; Thiazoles
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Dry eyes
- Phase II Corneal disorders
Most Recent Events
- 27 Jul 2022 No development reported - Phase-II for Corneal disorders in Japan (Ophthalmic) (NDR Batch 22)
- 23 Mar 2020 Senju Pharmaceuticals completes a phase II trial in Corneal disorders in Japan (Ophthalmic) (UMIN000034199)
- 15 Mar 2019 Senju Pharmaceutical completes the DELTA-1 phase III trial in Dry eyes in the US (NCT03527212)